Biogen acquires Alcyone Therapeutics for $85 million
LONDON: RTW Biotech Opportunities Ltd, the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, announced that Biogen Inc. has entered into a definitive agreement to acquire private portfolio company Alcyone Therapeutics, Inc. (“Alcyone”). Biogen will acquire Alcyone for an upfront cash payment of $85 million plus…